Yaya Capital

NeuralMed is a healthcare technology company that develops AI-driven solutions to analyze unstructured medical data from diverse sources. Its proprietary algorithms organize patient flow based on criticality, assist doctors in identifying pathologies, and structure reports using free texts and images. The solutions are reliable, easily integrated into existing systems, and enhance user adherence.

Founded in 2019, XP Health is a health tech startup offering an AI-powered vision benefits platform for employees and families. It uses facial recognition technology to recommend suitable eyewear from leading designers with high accuracy. The company works with businesses like Chegg and Zenefits, providing comprehensive virtual-first eye care at lower costs.

ISA is a digital-first home healthcare provider harnessing technology to bring care directly to patients' home, providing higher quality services at a fraction of the cost. Currently, ISA offers outpatient care, lab work services and immunizations. We are aiming to be the largest non-hospital healthcare company in Latam, by providing access to affordable healthcare services for millions of people through the decentralization of care.

Endpoint Health, Inc. is a precision immunology company focused on researching and developing therapies that enhance outcomes for patients with critical and immune-driven illnesses, including sepsis, acute respiratory distress syndrome, and COVID-19. Founded in 2018 and headquartered in Palo Alto, California, with additional offices in Detroit, Livonia, and Chicago, the company aims to overcome the limitations of traditional drug development by creating precision therapies tailored to individual patient needs. Utilizing its proprietary AI-powered platform, OMNAI, Endpoint Health identifies and matches high-potential therapies to patients most likely to benefit, ensuring personalized treatment that significantly improves health outcomes. The company is committed to delivering innovative solutions that address the complexities of autoimmune and inflammatory conditions.

Klivo Health is a health technology company focused on enhancing the quality of life for individuals with chronic diseases. The company operates a patient management platform designed to empower users to manage their health effectively. By providing real-time monitoring of medical conditions and facilitating the transmission of critical health data, such as blood glucose levels, Klivo Health enables healthcare professionals to achieve improved clinical outcomes. The platform also offers users access to information regarding clinical conditions and dietary guidance. Through its innovative approach, Klivo Health aims to add life to years rather than merely extending lifespan.

Endpoint Health, Inc. is a precision immunology company focused on researching and developing therapies that enhance outcomes for patients with critical and immune-driven illnesses, including sepsis, acute respiratory distress syndrome, and COVID-19. Founded in 2018 and headquartered in Palo Alto, California, with additional offices in Detroit, Livonia, and Chicago, the company aims to overcome the limitations of traditional drug development by creating precision therapies tailored to individual patient needs. Utilizing its proprietary AI-powered platform, OMNAI, Endpoint Health identifies and matches high-potential therapies to patients most likely to benefit, ensuring personalized treatment that significantly improves health outcomes. The company is committed to delivering innovative solutions that address the complexities of autoimmune and inflammatory conditions.

Metagenomi, Inc. is a genetic medicines company focused on developing innovative gene editing systems to address genetic diseases. Incorporated in 2016 and headquartered in Emeryville, California, Metagenomi utilizes metagenomics and machine learning to discover novel genome editing technologies. By sourcing cellular machinery from previously uncharacterized organisms, the company creates a proprietary toolbox that includes programmable nucleases, base editors, and advanced integration systems like prime editing and CRISPR-associated transposases. These systems are designed to be ultra-small, efficient, and highly specific, minimizing the risk of immune responses. Metagenomi aims to revolutionize gene editing techniques and deliver curative therapeutics to patients worldwide.